Drug firm Cadila Healthcare today said it will acquire 51 per cent stake in Windlass Healthcare for Rs 155.55 crore.
The deal does not constitute related party transaction, the company said in a BSE filing.
"Objective of this investment is to expand pharma manufacturing footprint," Cadila said.
As per the filing, the company has entered into an agreement to acquire 51 per cent share capital of Windlass Healthcare Pvt Ltd.
The cost of acquisition is Rs 155.55 crore and it will be completed by end of September 2018, it added.
Cadila stock closed 5.83 per cent down at Rs 354.55 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app